Risk factors modification:

- 1. Given that smoking appears to increase the risk of UIA formation, patients with UIA should be counseled regarding the importance of smoking cessation
- 2. Patients with UIA should monitor blood pressure and undergo treatment for hypertension.

Management:

- 3. Patients with an aSAH should undergo careful assessment for a coexistent UIA.
- 4. DSA is reasonable as the most sensitive imaging for follow-up of treated aneurysms.
- 5. CTA and MRA are useful for detection and follow-up of UIA.
- 6. It is reasonable to perform MRA as an alternative for follow-up for treated aneurysms, with DSA used as necessary when deciding on therapy.
- 7. Coiled aneurysms, especially those with wider neck or dome diameters or those that have residual filling, should have follow-up evaluation. The timing and duration of follow-up is uncertain, and additional investigation is necessary.
- 8. Patients with aneurysms with documented enlargement during follow-up should be offered treatment in the absence of prohibitive comorbidities
- 9. Treatment of UIAs in patients with a family history of IA is reasonable even in aneurysms at smaller sizes than spontaneously occurring IAs

Endovascular treatment:

- Use of coated coils is not beneficial compared with bare-metal coil
- Endovascular treatment of UIAs is recommended to be performed at high-volume centers.

Clipping versus coiling:

Endovascular coiling is associated with a reduction in procedural morbidity and mortality over surgical clipping in selected cases but has an overall higher risk of recurrence

Aneurysm Follow-Up (Patients Treated Without Surgery or Endovascular Coiling):

- Radiographic follow-up with MRA or CTA at regular intervals is indicated.
- First follow-up study at 6 to 12 months after initial discovery, followed by subsequent yearly or every other year follow-up, may be reasonable.
- It may be reasonable to consider TOF MRA rather than CTA for repeated long-term follow-up

Screening:

- Screening for aneurysms by MRA or CTA is indicated in:
 - Patients with ≥2 family members with IA or SAH
 - Patients with a history of autosomal dominant polycystic kidney disease,
 - Patients with coarctation of the aorta
 - Patients with microcephalic osteodysplastic primordial dwarfism

NeurologyResidents.Net